Immuneering Corporation IMRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -43.09%
- 1 year
- -41.58%
- Open
- 4.01
- Prev close
- 4.02
- Mkt cap
- 242.29M
- Vol
- 1.14M
- Avg vol
- 702.74K
- EPS
- -0.93
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.72
- High
- 4.07
- Forward P/E
- -1.34
- Beta
- -0.40
- Short ratio
- 1.19
- Inst. own
- 30.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 2.01
- 200-d avg
- 1.84
- 1y target
- 12.42
5D chart
Signals (70)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:15 PM | 4 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 12:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 9:50 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 9:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 9:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 9:35 AM | 6 days ago |
| RSI: Overbought | Oct 23, 3:25 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:15 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:15 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 3:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 2:50 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:40 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:10 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:10 PM | 1 week ago |
| MACD: Sell Signal | Oct 23, 1:00 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 12:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 11:35 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:30 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
News
2 days ago globenewswire.com
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in…
6 days ago globenewswire.com
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -…
1 month ago globenewswire.com
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in…
1 month ago globenewswire.com
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -
1 month ago globenewswire.com
Immuneering to Present at the ESMO Congress 2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
1 month ago defenseworld.net
Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX
Squarepoint Ops LLC decreased its position in shares of Immuneering Corporation (NASDAQ: IMRX) by 74.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the…
-
1 month ago benzinga.com
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the…
1 month ago globenewswire.com
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the…
1 month ago globenewswire.com
Immuneering to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
-
2 months ago benzinga.com
Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment
- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
2 months ago globenewswire.com
Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
2 months ago benzinga.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
2 months ago 247wallst.com
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.
-
2 months ago benzinga.com
Immuneering Q2 EPS $(0.27), Inline
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same…
2 months ago globenewswire.com
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on…
3 months ago seekingalpha.com
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is…
-
3 months ago benzinga.com
Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has…
3 months ago globenewswire.com
Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has…
-
3 months ago benzinga.com
Needham Maintains Buy on Immuneering, Raises Price Target to $18
Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.
3 months ago globenewswire.com
Immuneering Corporation Announces Grants of Inducement Awards
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously…
3 months ago zacks.com
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-
4 months ago benzinga.com
Immuneering Appoints Andrew Gengos CFO, Effective July 16
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as…
4 months ago globenewswire.com
Immuneering Appoints Andrew Gengos as Chief Financial Officer
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) --…
4 months ago zacks.com
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
-
4 months ago benzinga.com
Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed…
4 months ago globenewswire.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary…
5 months ago seekingalpha.com
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma
- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -- Only two categories of Grade 3+…
5 months ago benzinga.com
Crude Oil Edges Higher; US Consumer Sentiment Falls In May
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
5 months ago benzinga.com
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday
Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.
-
5 months ago benzinga.com
Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival…
-
5 months ago benzinga.com
Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 50 percent increase over losses of $(0.42)…
-
6 months ago benzinga.com
Immuneering To Present Updated Data From Phase 2a Clinical Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Pancreatic Cancer At 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -- The ASCO…
-
7 months ago benzinga.com
Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the…
-
8 months ago benzinga.com
Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58)…
9 months ago benzinga.com
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
9 months ago benzinga.com
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings
9 months ago benzinga.com
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 months ago benzinga.com
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
9 months ago benzinga.com
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
10 months ago benzinga.com
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
11 months ago benzinga.com
Earnings Scheduled For November 12, 2025
Earnings Scheduled For November 12, 2025
1 year ago benzinga.com
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
1 year ago benzinga.com
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session